AMG 220

Drug Profile

AMG 220

Alternative Names: C-326

Latest Information Update: 10 Sep 2008

Price : $50

At a glance

  • Originator Avidia
  • Developer Amgen
  • Class Anti-inflammatories; Proteins
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Crohn's disease

Most Recent Events

  • 25 Oct 2006 Avidia has been acquired by Amgen
  • 22 Sep 2006 Phase-I clinical trials in Crohn's disease in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top